Daniel Lebovic
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 10%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
- Hematology 25
- Multiple Myeloma Research and Treatments 24
-
- Protein Degradation and Inhibitors 13
- Co-authors
- Andrzej Jakubowiak (11 shared papers)Mark Kaminski (11 shared papers)Kent A. Griffith (12 shared papers)Sundar Jagannath (7 shared papers)Ravi Vij (7 shared papers)Keith Stockerl‐Goldstein (6 shared papers)Dominik Dytfeld (7 shared papers)Tara Anderson (6 shared papers)
- Journals
- Blood (23 papers)Journal of Clinical Oncology (3 papers)Clinical Cancer Research (2 papers)British Journal of Haematology (2 papers)JAMA Network Open (1 paper)
- Partner nations
- United StatesPolandSingapore
In The Last Decade
Daniel Lebovic
38 papers receiving 983 citations
Peers
Comparison fields: 5 of 56
- Hematology 557
- Oncology 427
- Genetics 135
- Pathology and Forensic Medicine 199
- Molecular Biology 712
Countries citing papers authored by Daniel Lebovic
This map shows the geographic impact of Daniel Lebovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Lebovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Lebovic more than expected).
Fields of papers citing papers by Daniel Lebovic
This network shows the impact of papers produced by Daniel Lebovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Lebovic. The network helps show where Daniel Lebovic may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Lebovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2012 | 311 | |
| 2 | 2015 | 162 | |
| 3 | 2014 | 133 | |
| 4 | 2016 | 65 | |
| 5 | 2018 | 30 | |
| 6 | 2013 | 28 | |
| 7 | 2018 | 27 | |
| 8 | 2014 | 26 | |
| 9 | 2013 | 26 | |
| 10 | 2011 | 23 | |
| 11 | 2011 | 18 | |
| 12 | 2012 | 14 | |
| 13 | 2010 | 13 | |
| 14 | 2013 | 13 | |
| 15 | 2013 | 13 | |
| 16 | 2010 | 12 | |
| 17 | 2011 | 11 | |
| 18 | 2012 | 11 | |
| 19 | 2014 | 10 | |
| 20 | 2014 | 9 |
About Daniel Lebovic
Daniel Lebovic is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Oncology and Genetics, having authored 41 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (13 papers), Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Peptidase Inhibition and Analysis (5 papers), Cancer Treatment and Pharmacology (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Hematology (557 citations), Oncology (427 citations), Genetics (135 citations), Pathology and Forensic Medicine (199 citations) and Molecular Biology (712 citations). Daniel Lebovic has collaborated with scholars based in United States, Poland and Singapore. Frequent co-authors include Andrzej Jakubowiak, Mark Kaminski, Kent A. Griffith, Sundar Jagannath, Ravi Vij, Keith Stockerl‐Goldstein, Dominik Dytfeld, Tara Anderson, Kristen Detweiler‐Short and M. Mietzel. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Haematology and JAMA Network Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.